The European Commission has approved Alexion Pharmaceuticals’ (NASDAQ:ALXN) Ultomiris (ravulizumab), a long-acting C5 complement inhibitor, for the treatment of adults and children with atypical hemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received Soliris (eculizumab) for at least three months and have evidence of response to eculizumab.
Atypical HUS is an ultra-rare disease that can cause progressive injury to vital organs, primarily the kidneys, via damage to the walls of blood vessels and blood clots.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.